Evidence mapPaperPMID 36268239Full record

ReviewHepatobiliary surgery and nutrition2022

Comparative effectiveness of medical treatment

Adrian T Billeter, Beatrice Reiners, Svenja E Seide, Pascal Probst, Eva Kalkum, Christian Rupp, Beat P Müller-Stich

Open access · diamondAbstract readReview
In one paragraph

Review in Hepatobiliary surgery and nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Rising in level of liver biomarkers after different types of bariatric surgery; is there any concern?Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026
    Article
  4. Endoscopic sleeve gastrectomyWorld journal of gastrointestinal pharmacology and therapeutics · 2025
    Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Adrian T BilleterDepartment of General, Visceral and Transplant Surgery, University of Heidelberg, Heidelberg, Germany.
Beatrice ReinersDepartment of General, Visceral and Transplant Surgery, University of Heidelberg, Heidelberg, Germany.
Svenja E SeideInstitute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Pascal ProbstDepartment of General, Visceral and Transplant Surgery, University of Heidelberg, Heidelberg, Germany.
Eva KalkumThe Study Center of the German Surgical Society (SDGC), Heidelberg, Germany.
Christian RuppDepartment of Gastroenterology and Hepatology, University of Heidelberg, Heidelberg, Germany.
Beat P Müller-StichDepartment of General, Visceral and Transplant Surgery, University of Heidelberg, Heidelberg, Germany.
Heidelberg University · DEGerman Society of Surgery · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Non-alcoholic steatohepatitis (NASH) comprises a major healthcare problem affecting up to 30% of patients with obesity and the associated risk for cardiovascular and liver-related mortality. Several new drugs for NASH-treatment are currently investigated. No study thus far directly compared surgical and non-surgical therapies for NASH. This network meta-analysis compares for the first time the effectiveness of different therapies for NASH using a novel statistical approach. Methods: The study was conducted according to the PRISMA guidelines for network meta-analysis. PubMed, CENTRAL and Web of Science were searched without restriction of time or language using a validated search strategy. Studies investigating therapies for NASH in adults with liver biopsies at baseline and after at least 12 months were selected. Patients with liver cirrhosis were excluded. Risk of bias was assessed with ROB-2 and ROBINS-I-tools. A novel method for population-adjusted indirect comparison to include and compare single-arm trials was applied. Main outcomes were NASH-resolution and improvement of fibrosis. Results: Out of 7,913 studies, twelve randomized non-surgical studies and twelve non-randomized surgical trials were included. NASH-resolution after non-surgical intervention was 29% [95% confidence interval (CI): 23-40%] and 79% (95% CI: 72-88%) after surgery. The network meta-analysis showed that surgery had a higher chance of NASH-resolution than medication [odds ratio (OR) =2.68; 95% CI: 1.44-4.97] while drug treatment was superior to placebo (OR =2.24; 95% CI: 1.55-3.24). Surgery (OR =2.18; 95% CI: 1.34-3.56) and medication (OR =1.79; 95% CI: 1.39-2.31) were equally effective to treat fibrosis compared to placebo without difference between them. The results did not change when only new drugs specifically developed for the treatment of NASH were included. Conclusions: Metabolic surgery has a higher effectiveness for NASH-therapy than medical therapy while both were equally effective regarding improvement of fibrosis. Trials directly comparing surgery with medication must be urgently conducted. Patients with NASH should be informed about surgical treatment options.

Indexed as

fatty livermetabolic surgeryNon-alcoholic fatty liver disease (NAFLD)non-alcoholic steatohepatitis (NASH)

Identifiers

PMID36268239
PMCPMC9577982
OpenAlexW3200862539

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.